Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)
Authors not listed
Ionis Pharmaceuticals, Inc. · 2024
Abstract
The primary purpose of this study is to evaluate the safety and tolerability of ION269 in adults with Down syndrome with evidence of brain amyloid positivity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2024). A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study). <em>Ionis Pharmaceuticals, Inc.</em>. https://clinicaltrials.gov/study/NCT06673069
Vancouver
Anonymous. A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study). Ionis Pharmaceuticals, Inc.. 2024.
BibTeX
@misc{anon2024APhase,
title = {A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)},
author = {Anonymous},
journal = {Ionis Pharmaceuticals, Inc.},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alpha Cognition, Inc 2026
Open access · US-GOV
RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease
Miracle Biomedical Co., Ltd. 2026
Open access · US-GOV
A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of MiraMSC Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome
Chong Kun Dang Pharmaceutical 2019
Open access · US-GOV
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
Abbott 2009
Open access · US-GOV
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
Meribank Biotech Co., Ltd. 2024
Open access · US-GOV
A Two-part, Phase I/II, Randomized, Single-blind Study to Evaluate the Efficacy and Safety of UMC119-06-05 in Older Adults With Pre-frailty & Frailty
Janssen Research & Development, LLC 2013
Open access · US-GOV